Skip to content
★ Sign in to follow
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. Stock: price and insider trades · China

博腾股份

CN·Mcap CN¥11.5BHealth Care

Porton Pharma Solutions Ltd.: what insiders have been doing

Insider filings for Porton Pharma Solutions Ltd. are scarce in the SSE / SZSE (CSRC) feed, the latest one published on 28 March 2022. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€2M
1 ops. · all time

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 19,065 of 26,914 companies
37.5
score / 100
Value
38
Quality
37
FCF yld4.0%
Earn yld0.8%
EV/EBITDA23.3x
ROE-4.2%
Gross mgn30%
Net mgn2.8%
Debt/EBITDA2.7x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥21.25
Analyst consensus
1 analysts
1.00/5
CN¥30.00Target CN¥30.00(+41%)CN¥30.00
Income statement
RevenueCN¥3.4B
Gross profitCN¥1B30% margin
EBITDACN¥559.4M16% margin
Net incomeCN¥96.3M-4.3% margin
Valuation
PER (trailing)62.4x
PER (forward)36.6x
P/Book2.3x
Beta0.55
Balance sheet & cash
Market capCN¥11.5B
Total debtCN¥1.5B
Free Cash FlowCN¥464.4M
Debt / Equity25%
Profitability & ownership
ROE-4.2%
ROA1.4%
% insiders44.7%
% institutions4.6%
Last declaration on 28 March 2022
Declarations1 total
  • ▼
    高管Executives
    15M CNY19SZSE
    150,000 shares100.0% of flowA股XSHESZSE:173000005392308580

1 of 1 declaration

About Porton Pharma Solutions Ltd.

博腾股份 is a company focused on the health and pharmaceutical sector, providing innovative solutions for drug development. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations